LIVE BLOG| It’s All in the Vehicle
In this live blog from the SDPA Annual Summer Dermatology Conference in Austin, TX, Leon Kircik, MD presented a product theater for Promius Pharma called “It’s All In The Vehicle.”
- Sernivo (betamethasone diproprionate 0.05%) spray is approved for the treatment of mild to moderate plaque psoriasis in patient ages 18 years of age and older
- Sernivo was shown effective in extensive moderate psoriasis patients (including patients with 10-20% BSA and difficult to treat plaques on the elbows and knees)
- Sernivo is a novel oil in water emulsion that will not dry or irritate skin
- Sernivo penetrates thick plaques with limited systemic absorption, and is delivered as a spray, but feels like a creamy lotion.
Dr. Kircik described Promius Pharma’s Sernivo (betamethasone diproprionate 0.05%) spray for the treatment of mild to moderate plaque psoriasis. He zeroed in on the new product’s ability to penetrate and permeate the skin without being absorbed systemically.
Dr. Kircik noted that the clinical efficacy of Sernivo is on par with strong topical steroid products with an excellent safety profile and limited adverse events. Dr. Kircik also added that Sernivo is effective in treating extensive psoriasis including difficult to treat plaques on elbows and knees.
Dr. Kircik highlighted the ability of Sernvio to achieve treatment success of “clear or almost clear” in nearly 40% of patients. A secondary endpoint showed that at least a 50% improvement in total sign score (based on erythema, scaling, and plaque elevation) was achieved by Sernivo. In addition, the percentage of participants experiencing pruritis dropped from 65% to 35% by day four, then to 23% by day 29.
Dr. Kircik added that Sernivo has been shown to have a strong safety profile with minimal adverse drug events.